Table III.

Liposomal formulations of curcumin for parenteral administration.

Formulation	Method	Particle Size (nm)	Encapsulation Efficiency (%)	Advantages	Refs.
DMPC:DMPG:Cholesterol (7:1:8) liposomes of curcumin for parenteral administration.	Vortexing of SMLs	N. R.	N. R.	Increased curcumin stability in PBS. Increased efficacy in inhibiting ConA stimulated human lymphocytes and EBV transformed B- cells.	80
Pegylated DMPC, Cholesterol, DMPG liposomes of curcumin for parenteral administration.	Extrusion through 0.22 µm filter	N. R.	N. R.	Significant growth inhibition of Colo205 and LoVo cells in nude xenograft mice.	79
DMPC:DMPG (9:1) liposomes of curcumin for parenteral administration.	Extrusion through 0.22 µm filter	N. R.	N. R.	Significant growth inhibition of CAL27 cells in nude xenograft mice.	81
DMPC liposomes coated with PSA specific antobodies.	Sonication of SUVs	100–150	N. R.	Increased inhibition of LNCaP and C4-2B cells at 10 fold lower doses of curcumin	34

N. R.: Not Reported